Keyword: Johnson & Johnson
UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.
The first product from Ethicon's collaboration with Grifols, the Vistaseal spray combines two clotting agents to control surgical bleeds.
J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.
Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.
With the failure of its lead program in pancreatic cancer, Halozyme is cutting drug development to focus solely on its drug delivery technology.
Most top R&D executives from across biopharma are earning around $7 million a year.
2. Paul Stoffels, Johnson & Johnson
The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.
The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,
